Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.5700-0.0400 (-1.11%)
At close: 04:00PM EDT
3.6400 +0.07 (+1.96%)
After hours: 05:24PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.6100
Open3.9300
Bid3.5400 x 100
Ask3.6000 x 300
Day's range3.5400 - 4.0700
52-week range1.6300 - 8.8300
Volume2,876,659
Avg. volume2,396,077
Market cap406.38M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)-1.9200
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.64
  • GlobeNewswire

    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on June 1, 2024 the Company granted (i) a non-qualified stock option to one newly-hired employee to purchase a total of 65,000 shares of the Company’s common stock at an exercise p

  • GlobeNewswire

    Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

    SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York. A l

  • Insider Monkey

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is […]